The estimated Net Worth of Jon Faiz Kayyem is at least $6.26 Milione dollars as of 5 June 2024. Jon Kayyem owns over 57,549 units of Biodesix Inc stock worth over $2,059,234 and over the last 14 years Jon sold BDSX stock worth over $4,199,281.
Jon has made over 70 trades of the Biodesix Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently Jon bought 57,549 units of BDSX stock worth $996,749 on 5 June 2024.
The largest trade Jon's ever made was buying 286,786 units of Biodesix Inc stock on 31 May 2024 worth over $4,926,983. On average, Jon trades about 12,093 units every 49 days since 2010. As of 5 June 2024 Jon still owns at least 1,150,410 units of Biodesix Inc stock.
You can see the complete history of Jon Kayyem stock trades at the bottom of the page.
Jon's mailing address filed with the SEC is C/O INHIBRX BIOSCIENCES, INC., 11025 NORTH TORREY PINES ROAD, SUITE 140, LA JOLLA, CA, 92037.
Over the last 4 years, insiders at Biodesix Inc have traded over $0 worth of Biodesix Inc stock and bought 32,782,268 units worth $58,800,766 . The most active insiders traders include Jack W Schuler, Lawrence T. Jr Kennedy e Matthew Strobeck. On average, Biodesix Inc executives and independent directors trade stock every 12 days with the average trade being worth of $567,788. The most recent stock trade was executed by Chris Vazquez on 8 August 2024, trading 602 units of BDSX stock currently worth $1,078.
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
Biodesix Inc executives and other stock owners filed with the SEC include: